Select Page

TIL (Small Cap - Next Multibagger) Share Target 2024, 2025 To 2039

TIL Limited

Company Logo Price: ₹290.80
52 Week Low: ₹148.14
52 Week High: ₹588.85
Market Capital: 1,630.41 Crore (Smallcap)
Healthcare -> Biotechnology
Show Table of Contents

To predict the TIL's future market prices, we harnessed 2 dynamic approaches:

Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices

Approach 1: Technical Analysis Paired With Price Action

TIL Share Price Target For 2024

The line chart displays the monthly closing prices of TIL with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.

For detailed target and stop loss values for TIL shares in 2024, see the table below.

TIL Share Price Target Table For 2024

Level Value Analysis
2024 Target 3 303.8 (+4.47%) Price Action: Mar 2017 High
2024 Target 2 300.25 (+3.24%) Price Action: 10 Oct 2024 Low
2024 Target 1 297.15 (+2.18%) Price Action: Nov 2023 Low
Current Price 290.80 TIL's share price as of 26 Dec 2024
Stop Loss 1 287.6 (-1.11%) Price Action: Dec 2024 Low
Stop Loss 2 284.7 (-2.1%) Price Action: 28 Aug 2023 Low
Stop Loss 3 281.8 (-3.1%) Price Action: 25 Sep 2023 Low

Short-Term Technical Outlook

Current Technical Position: TIL is displaying bearish momentum trading below key moving averages.

Key Technical Level: The 25-day moving average at ₹302.24 serves as the nearest technical reference point.

Historical Returns: 3-month: -14.36% | 6-month: -5.81% | 1-year: -22.48%

TIL Share Price Target For 2025

The line chart displays the monthly closing prices of TIL with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.

For detailed target and stop loss values for TIL shares in 2025, see the table below.

TIL Share Price Target Table For 2025

Level Value Analysis
2025 Target 3 575.0 (+97.73%) Price Action: 05 Mar 2024 Low
2025 Target 2 564.75 (+94.2%) Price Action: 07 Mar 2024 Low
2025 Target 1 557.5 (+91.71%) Price Action: 29 Feb 2024 High
Current Price 290.80 TIL's share price as of 26 Dec 2024
Stop Loss 1 224.0 (-22.98%) Price Action: 24 Apr 2024 High
Stop Loss 2 219.65 (-24.47%) Price Action: 23 Apr 2024 High
Stop Loss 3 217.4 (-25.25%) Price Action: 25 Jul 2023 High

Long-Term Technical Outlook

52-Week Range Analysis: TIL is currently trading at 32.4% of its 52-week range (₹148.14 - ₹588.85).

Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.

Long-Term Performance: 1-year: -22.48% | 3-year: +107.79% | 5-year: +66.5%

Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!

Join our WhatsApp group

Join our Telegram group

Your phone number will be HIDDEN to other users.

Approach 2: Machine Learning By Studying Historical Prices

TIL Share Price Target Chart and Table From 2024, 2025, 2026 to 2039

Year Target 1 Target 1 YoY Chg % Target 2
Current Price ₹290.80
2024 ₹334.66 +15.08% ₹339.68
2025 ₹360.16 +7.61% ₹365.56
2026 ₹348.98 -3.1% ₹367.30
2027 ₹355.87 +1.97% ₹390.23
2028 ₹409.16 +14.97% ₹415.30
2029 ₹424.17 +3.66% ₹430.53
2030 ₹451.59 +6.46% ₹458.36
2031 ₹433.29 -4.05% ₹459.00
2032 ₹437.89 +1.06% ₹481.92
2033 ₹499.30 +14.02% ₹506.79
2034 ₹513.67 +2.87% ₹521.38
2035 ₹543.03 +5.71% ₹551.18
2036 ₹517.61 -4.68% ₹550.70
2037 ₹519.91 +0.44% ₹573.62
2038 ₹589.45 +13.37% ₹598.29
2039 ₹570.65 -3.18% ₹611.61

Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.

TIL Brief Company Overview

Instil Bio: Pioneering Cell Therapy Innovations Instil Bio, Inc. is a leading clinical-stage biopharmaceutical company dedicated to developing a pipeline of novel therapies for cancer treatment. Incorporated in 2018 and headquartered in Dallas, Texas, Instil Bio has quickly... established itself as a reputable force in the industry. Their key product, CoStAR-TIL, is a cell therapy that harnesses the power of tumor-infiltrating lymphocytes (TILs) to combat cancer. Instil Bio is actively developing other cutting-edge TIL technologies, expanding their product range. Driven by a profound commitment to innovation and patient outcomes, Instil Bio's team of experts continues to push the boundaries of cancer treatment.

TIL Financial Performance

Metric Value Description
Market Capital 1,630.41 Crore Market valuation of TIL's shares.
Revenue (TTM) 51.34 Crore Total revenue generated by TIL over the past twelve months.
Net Income (TTM) +68.4 Crore Net Profit or Loss after all the expenses over the past twelve months.
Operating Margin -79.27% Income from operations as a percentage of revenue, before taxes and interest.
Profit Margin +133.24% Net income as a percentage of revenue, after all expenses.
Revenue Growth
(Quarterly)
+8.6% Change in revenue compared to the previous quarter.
Debt-to-Equity
(D/E) Ratio
-0.76 Company's total debt divided by total shareholder equity.
Total Debt 236.68 Crore Sum of TIL's current & long-term financial obligations.
Total Cash 1.05 Crore Total amount of liquid funds available to TIL.
Beta 1.22 Beta is greater than 1 indicating that the TIL's price is more volatile than the market.

Is TIL A Good Buy For Long Term?

TIL's recent performance indicates potential for long-term growth. Despite a revenue increase and strong profit margin, concerns arise due to its high debt-to-equity ratio. However, positive annualized returns over the past 3 and 5 years suggest resilience. With a market capitalization of over 1,630 crores, TIL is a stable small-cap stock that could offer long-term value if the debt situation improves.

Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.

All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.